Comparison of oral dydrogesterone and vaginal micronized progesterone for luteal phase support in intrauterine insemination

Abstract

This study aims to compare the pregnancy outcomes of vaginal micronized progesterone capsules with oral dydrogesterone in subjects with unexplained subfertility who are undergoing IUI in conjunction with ovarian stimulation by using rFSH. A total of 432 patients with unexplained subfertility who underwent IUI in conjunction with ovarian stimulation were enrolled in this retrospective study. Patients were randomized into two groups: (1) dydrogesterone or (2) vaginal micronized progesterone capsules, for luteal phase support. Clinical pregnancy and live birth were the primary outcome measures of the present study. Dydrogesterone was used in 233 participants (54%) and 337 cycles, while 199 participants (46%) and 233 cycles received vaginal micronized progesterone capsule treatment. The proportion of clinical pregnancies (7.4% vs. 10.2%, p = .213), live births (68% vs. 73%, p = .286) were similar in the two groups. Oral dydrogesterone and vaginal micronized progesterone provide similar pregnancy outcomes in terms of clinical pregnancy and live birth rates in women undergoing IUI in conjunction with ovarian stimulation with rFSH. Given the simple and easy administration, lack of safety concerns and better patient tolerability, we suggest that oral dydrogesterone might be preferred for luteal phase support in IUI.

摘要:

本研究旨在比较不明原因不孕症患者接受IUI联合使用rFSH促排卵治疗后应用阴道微粒化黄体酮胶囊与口服地屈孕酮的妊娠结局。在这项回顾性研究中, 共有432名不明原因的不孕症患者在促排卵的同时接受了IUI治疗。患者被随机分为两组：(1)地屈孕酮(2)阴道微粒化黄体酮胶囊, 用于黄体期支持。临床妊娠和活产是本研究的主要结果指标。233名患者(54%)和337个周期应用了地屈孕酮, 199名患者(46%)和233个周期应用了阴道微粒化黄体酮胶囊治疗。两组的临床妊娠率(7.4%vs.10.2%, p=.213)、活产率(68%vs.73%, p=.286)相似。在接受IUI联合rFSH促排卵的女性中, 口服地屈孕酮和阴道应用微粒化黄体酮在临床妊娠和活产率方面有相似的妊娠结局。考虑到给药简单易行、没有安全顾虑以及患者较好的耐受性, 我们建议口服地屈孕酮可能是IUI黄体期支持的首选药物。

The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.

Keywords:

• Intrauterine insemination
• luteal support
• vaginal progesterone
• dydrogesterone

Disclosure statement

The authors have no conflict of interest in this study.